During transsphenoidal resection of pituitary tumors and cysts, surgery is performed by a
neurosurgeon and ear nose and throat surgeon. The pituitary tumor or cyst is reached by
making a small hole in the back of the nose into the bottom of the skull. The surgeon is able
to see the pituitary and tumor with an endoscope and remove the tumor through the hole.
Surgery on the pituitary can cause disruption in the secretion of ACTH and cause adrenal
failure (lack of cortisol secretion) which can cause nausea, vomiting, low blood pressure,
and rarely can be fatal. There is no consensus among endocrinologists and neurosurgeons about
the use of perioperative steroids in pituitary patients. Traditionally, all patients
undergoing pituitary surgery were given steroids before, during, and after surgery because of
the assumption that there would be some compromise in the amount of ACTH released by the
pituitary as a result of surgical trauma. Studies have failed to show, however, that ACTH
secretion is in fact compromised during transsphenoidal pituitary microsurgery. As a result,
there are some centers that routinely give perioperative steroids to all patients undergoing
pituitary surgery and there are some centers that do not routinely give perioperative
steroids. There are several retrospective and prospective studies that have addressed this
issue and have shown that withholding perioperative steroids is safe, but there has never
been a prospective study comparing the two approaches.
Objectives: The goal of this study is to prospectively compare two approaches to the
perioperative management of patients undergoing transsphenoidal resection of a pituitary
tumor or cyst. One protocol includes the routine use of perioperative steroids and the other
does not. The investigators hypothesis, based on previous studies, is that patients who are
adrenally sufficient do not routinely need to be treated with perioperative steroids. The
investigators also hypothesize that the use of perioperative steroids may be associated with
a higher rate of adverse outcomes